BR112018008503A2 - método para tratar câncer de pulmão de células pequenas, método para tratar um sujeito, método para selecionar um sujeito com câncer - Google Patents
método para tratar câncer de pulmão de células pequenas, método para tratar um sujeito, método para selecionar um sujeito com câncerInfo
- Publication number
- BR112018008503A2 BR112018008503A2 BR112018008503A BR112018008503A BR112018008503A2 BR 112018008503 A2 BR112018008503 A2 BR 112018008503A2 BR 112018008503 A BR112018008503 A BR 112018008503A BR 112018008503 A BR112018008503 A BR 112018008503A BR 112018008503 A2 BR112018008503 A2 BR 112018008503A2
- Authority
- BR
- Brazil
- Prior art keywords
- subject
- treating
- cancer
- small cell
- cell lung
- Prior art date
Links
- 206010041067 Small cell lung cancer Diseases 0.000 title abstract 2
- 208000000587 small cell lung carcinoma Diseases 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000012661 PARP inhibitor Substances 0.000 abstract 2
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 abstract 2
- QUQKKHBYEFLEHK-QNBGGDODSA-N chembl3137318 Chemical class CC1=CC=C(S(O)(=O)=O)C=C1.CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 QUQKKHBYEFLEHK-QNBGGDODSA-N 0.000 abstract 1
- HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229950004550 talazoparib Drugs 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Abstract
trata-se de métodos de tratamento de um sujeito com câncer de pulmão de células pequenas que expressa schlafen-11 (slfn11) com um inibidor de parp ou com talazoparibe ou um sal farmaceuticamente aceitável do mesmo. especificamente, o método compreende detectar slfn 11 em uma amostra de célula tumoral do sujeito e administrar a quantidade eficaz de um inibidor de parp, tal como talazoparibe ou o sal de tosilato de talazoparibe ao sujeito.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562246538P | 2015-10-26 | 2015-10-26 | |
PCT/US2016/058928 WO2017075091A1 (en) | 2015-10-26 | 2016-10-26 | Treatment of small cell lung cancer with a parp inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018008503A2 true BR112018008503A2 (pt) | 2018-10-23 |
Family
ID=58631864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018008503A BR112018008503A2 (pt) | 2015-10-26 | 2016-10-26 | método para tratar câncer de pulmão de células pequenas, método para tratar um sujeito, método para selecionar um sujeito com câncer |
Country Status (13)
Country | Link |
---|---|
US (1) | US20190054087A1 (pt) |
EP (1) | EP3368041A4 (pt) |
JP (1) | JP2018536700A (pt) |
KR (1) | KR20180100546A (pt) |
CN (1) | CN108883115A (pt) |
AU (1) | AU2016346351A1 (pt) |
BR (1) | BR112018008503A2 (pt) |
CA (1) | CA3003422A1 (pt) |
IL (1) | IL258900A (pt) |
MX (1) | MX2018005071A (pt) |
RU (1) | RU2018119128A (pt) |
SG (1) | SG11201803462PA (pt) |
WO (1) | WO2017075091A1 (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110087730B (zh) | 2016-09-27 | 2023-03-28 | 百济神州(苏州)生物科技有限公司 | 使用包含parp抑制剂的组合产品治疗癌症 |
AU2018270112A1 (en) | 2017-05-18 | 2019-12-12 | Tesaro, Inc. | Combination therapies for treating cancer |
US20200171082A1 (en) * | 2017-06-20 | 2020-06-04 | Nantomics, Llc | Quantifying slfn11 protein for optimal cancer therapy |
EP3654985A4 (en) * | 2017-07-17 | 2021-04-07 | BeiGene, Ltd. | TREATMENT OF CANCER WITH A COMBINATION OF PARP INHIBITORS, TEMOZOLOMIDE AND / OR RADIATION THERAPY |
WO2019067978A1 (en) | 2017-09-30 | 2019-04-04 | Tesaro, Inc. | POLYTHERAPIES FOR THE TREATMENT OF CANCER |
CN111182923A (zh) | 2017-10-06 | 2020-05-19 | 特沙诺有限公司 | 组合疗法及其用途 |
BR112020006371A2 (pt) | 2017-10-13 | 2020-09-29 | Merck Patent Gmbh | combinação de um inibidor de parp e um antagonista de ligação de eixo de pd-1 |
TW201938165A (zh) | 2017-12-18 | 2019-10-01 | 美商輝瑞股份有限公司 | 治療癌症的方法及組合療法 |
TW201929902A (zh) * | 2017-12-27 | 2019-08-01 | 美商提薩羅有限公司 | 治療癌症之方法 |
WO2020095184A1 (en) | 2018-11-05 | 2020-05-14 | Pfizer Inc. | Combinations for treating cancer |
WO2021181233A2 (en) | 2020-03-09 | 2021-09-16 | Pfizer Inc. | Fusion proteins and uses thereof |
CA3201467A1 (en) * | 2020-11-13 | 2022-05-19 | Pfizer Inc. | Talazoparib soft gelatin capsule dosage form |
KR20230118597A (ko) | 2020-12-07 | 2023-08-11 | 화이자 인코포레이티드 | 탈라조파립을 사용한 치료에 감수성인 종양을 확인하는방법 및 그의 치료 방법 |
EP4304653A1 (en) * | 2021-03-10 | 2024-01-17 | Astrazeneca AB | Methods for treating small cell lung cancer and other neuroendocrine cancers |
CA3214316A1 (en) | 2021-03-24 | 2022-09-29 | Pfizer Inc. | Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer |
WO2023131894A1 (en) | 2022-01-08 | 2023-07-13 | Pfizer Inc. | Genomic loss of heterozygosity as a predictive biomarker for treatment with talazoparib and methods of treatment thereof |
WO2024074959A1 (en) | 2022-10-02 | 2024-04-11 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
WO2024090805A1 (ko) * | 2022-10-27 | 2024-05-02 | 이원다이애그노믹스(주) | 폐암 진단용 메틸화 마커 및 이의 조합 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201032796A (en) * | 2009-02-04 | 2010-09-16 | Bipar Sciences Inc | Treatment of lung cancer with a PARP inhibitor in combination with a growth factor inhibitor |
CA2787844C (en) * | 2010-02-03 | 2019-08-27 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency |
US20130317027A1 (en) * | 2010-03-01 | 2013-11-28 | Myrexis, Inc. | Compounds and therapeutic uses thereof |
KR20210028747A (ko) * | 2010-10-21 | 2021-03-12 | 메디베이션 테크놀로지즈 엘엘씨 | 결정질의 (8s,9r)-5-플루오로-8-(4-플루오로페닐)-9-(1-메틸-1h-1,2,4-트리아졸-5-일)-8,9-디하이드로-2h-피리도[4,3,2-de]프탈라진-3(7h)-온 토실레이트 염 |
CA3172586A1 (en) * | 2013-07-31 | 2015-02-05 | Avalyn Pharma Inc. | Aerosol imatininb compounds and uses thereof |
-
2016
- 2016-10-26 KR KR1020187014869A patent/KR20180100546A/ko unknown
- 2016-10-26 CN CN201680076067.0A patent/CN108883115A/zh active Pending
- 2016-10-26 EP EP16860716.6A patent/EP3368041A4/en not_active Withdrawn
- 2016-10-26 WO PCT/US2016/058928 patent/WO2017075091A1/en active Application Filing
- 2016-10-26 RU RU2018119128A patent/RU2018119128A/ru not_active Application Discontinuation
- 2016-10-26 JP JP2018541106A patent/JP2018536700A/ja active Pending
- 2016-10-26 SG SG11201803462PA patent/SG11201803462PA/en unknown
- 2016-10-26 BR BR112018008503A patent/BR112018008503A2/pt not_active Application Discontinuation
- 2016-10-26 MX MX2018005071A patent/MX2018005071A/es unknown
- 2016-10-26 CA CA3003422A patent/CA3003422A1/en not_active Abandoned
- 2016-10-26 AU AU2016346351A patent/AU2016346351A1/en not_active Abandoned
- 2016-10-26 US US15/771,086 patent/US20190054087A1/en not_active Abandoned
-
2018
- 2018-04-24 IL IL258900A patent/IL258900A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3368041A1 (en) | 2018-09-05 |
AU2016346351A1 (en) | 2018-05-24 |
EP3368041A4 (en) | 2019-07-17 |
IL258900A (en) | 2018-06-28 |
KR20180100546A (ko) | 2018-09-11 |
SG11201803462PA (en) | 2018-05-30 |
CA3003422A1 (en) | 2017-05-04 |
JP2018536700A (ja) | 2018-12-13 |
CN108883115A (zh) | 2018-11-23 |
MX2018005071A (es) | 2018-11-29 |
WO2017075091A1 (en) | 2017-05-04 |
US20190054087A1 (en) | 2019-02-21 |
RU2018119128A (ru) | 2019-11-28 |
RU2018119128A3 (pt) | 2020-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018008503A2 (pt) | método para tratar câncer de pulmão de células pequenas, método para tratar um sujeito, método para selecionar um sujeito com câncer | |
PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
BR112017020973A2 (pt) | método para tratar câncer em um paciente | |
EA201691866A1 (ru) | Проникающие в опухоль лимфоциты для адоптивной клеточной терапии | |
EA201790398A1 (ru) | Способы лечения заболевания печени | |
BR112016017700A2 (pt) | método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit | |
CL2016000373A1 (es) | Beneficio de supervivencia en pacientes con tumores sólidos con niveles elevados de proteína c reactiva | |
PE20180260A1 (es) | Metodos y kits para tratar la depresion | |
EA201790142A1 (ru) | Лечение лейкоза ингибиторами гистондеацетилазы | |
BR112017016019A2 (pt) | método para tratamento de câncer, artigo para fabricação, e, kit. | |
BR112015020466A2 (pt) | inibidores de cdc7 | |
BR112017004349A2 (pt) | terapia com gene de globina para o tratamento de hemoglobinopatias | |
MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
DOP2015000297A (es) | Composiciones y metodos para tratar anemia | |
IN2014DN09678A (pt) | ||
BR112015023020A2 (pt) | combinação de inibidor de egfr t790m e inibidor de egfr para o tratamento de câncer pulmonar de células não-pequenas | |
WO2019090347A8 (en) | Adenosine pathway inhibitors for cancer treatment | |
EA201591543A1 (ru) | Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki | |
DOP2019000019A (es) | Metodos para tratar el cancer de prostata | |
MX2016016388A (es) | Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña. | |
NZ712691A (en) | C. novyi for the treatment of solid tumors in humans | |
MX2017011018A (es) | Inhibicion de la actividad de olig2. | |
MX2015011386A (es) | Metodo para tratar cancer pancreatico. | |
ZA201901367B (en) | Inhibition of olig2 activity | |
BR112016015997A2 (pt) | ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |